KYMERA THERAPEUTICS INC. - COMMON STOCK

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

22 May 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

19 May 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

18 May 2023 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

04 May 2023 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4

11 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

01 Mar 2023 07:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

23 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23

01 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

10 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

04 Jan 2023 07:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

03 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials

14 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

12 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

11 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

01 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

03 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors

03 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Third Quarter 2022 Results on November 3

20 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

13 Oct 2022 16:15:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

15 Sep 2022 07:30:00 By Nasdaq GlobeNewswire